{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:29:55Z","timestamp":1792646995254,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,2,15]]},"abstract":"<jats:p> PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg\/m<jats:sup>2<\/jats:sup> by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. <\/jats:p><jats:p> RESULTS: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg\/m<jats:sup>2<\/jats:sup>. Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. <\/jats:p><jats:p> CONCLUSION: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered. <\/jats:p>","DOI":"10.1200\/jco.2002.20.4.937","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:46:55Z","timestamp":1487926015000},"page":"937-940","source":"Crossref","is-referenced-by-count":215,"title":["Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer"],"prefix":"10.1200","volume":"20","author":[{"given":"David J.","family":"Vaughn","sequence":"first","affiliation":[{"name":"From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Broome","sequence":"additional","affiliation":[{"name":"From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[{"name":"From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Gutheil","sequence":"additional","affiliation":[{"name":"From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi B.","family":"Markowitz","sequence":"additional","affiliation":[{"name":"From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-103603","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)48996-8"},{"key":"R2-103603","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38733-5"},{"key":"R3-103603","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39548-4"},{"key":"R4-103603","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7"},{"key":"R5-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.1050"},{"key":"R6-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"R7-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"R8-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2564"},{"key":"R9-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2264"},{"key":"R10-103603","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65459-4"},{"key":"R11-103603","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.106"},{"key":"R12-103603","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66765-X"},{"key":"R13-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3353"},{"key":"R14-103603","unstructured":"Perez  EA,   Irwin  DH,   Patel  R,  et al:   A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer.  Proc Am Soc Clin Oncol 18:  126a,1999  (abstr 480)"},{"key":"R15-103603","unstructured":"Breier  S,   Lebedinsky  C,   Ayiviri  A,  et al:   Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC):  A phase II trial in pretreated patients (pts).   Proc Am Soc Clin Oncol 17:  192a,1998  (abstr 740)"},{"key":"R16-103603","unstructured":"Chang  AY,   Boros  L,   Asbury  R,  et al:   Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.  Semin Oncol 24:  S17,1997-S71,    (5 suppl 17)"},{"key":"R17-103603","doi-asserted-by":"crossref","unstructured":"Fennelly  D,   Aghajanian  C,   Shapiro  F,  et al:   Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.  J Clin Oncol 15:  187,1995-192,","DOI":"10.1200\/JCO.1997.15.1.187"},{"key":"R18-103603","doi-asserted-by":"crossref","unstructured":"Klaassen  U,   Wilke  H,   Strumbers  D,  et al:   Phase I study with a weekly one hour infusion of paclitaxel in patients with metastatic breast and ovarian cancer.  Eur J Cancer 32A:  547,1996-549,","DOI":"10.1016\/0959-8049(95)00641-9"},{"key":"R19-103603","unstructured":"Abu-Rustum  NR,   Aghajanian  C,   Barakat  RR,  et al:   Salvage weekly paclitaxel in recurrent ovarian cancer.  Semin Oncol 24:  62,1997-67,     (suppl 15)"},{"key":"R20-103603","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R21-103603","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"R22-103603","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910315)67:6<1525::AID-CNCR2820670611>3.0.CO;2-8"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.4.937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:55:45Z","timestamp":1653515745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.4.937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,15]]},"references-count":22,"aliases":["10.1200\/jco.20.4.937"],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,2,15]]}},"alternative-id":["10.1200\/JCO.2002.20.4.937"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.4.937","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,15]]}}}